Leading expert, Prof. Nick Harvey, Professor of Rheumatology and Clinical Epidemiology, Honorary Consultant Rheumatologist at the University of Southampton (UK), Vice Chair of IOF’s Committee of Scientific Advisors (CSA), will be the speaker of this much anticipated 1-hour Capture the Fracture® webinar. WHEN: January 16, 11:00-12:00 CET Read more
On April 28th, the U.S. Food and Drug Administration (FDA) approved Abaloparatide, a new osteoanabolic agent for the treatment of postmenopausal women with osteoporosis who are at high risk for fracture — patients who have had a prior osteoporotic fracture, have multiple fracture risk factors, or have failed or cannot tolerate other osteoporosis therapies. Read more
El 28 de abril pasado, la Administración de Drogas y Alimentos de los Estados Unidos (FDA) aprobó el Abaloparatide. Se trata de un nuevo agente osteoanabólico para el tratamiento de mujeres posmenopáusicas con osteoporosis y que tienen un alto riesgo de fractura como aquellas pacientes que tuvieron una fractura osteoporótica previa, que presentan múltiples factores de riesgo de fractura o que han... Read more
A new Position Statement, jointly published by seven international and European organizations, identifies fracture-related risk factors in patients treated by aromatase-inhibitors (AI) and outlines key management strategies to help prevent bone loss and related fractures. Read more
IOF is pleased to announce that the UK National Osteoporosis Guideline Group (NOGG) 2017 Update has now been released via the NOGG website (  This new Guideline, accredited by NICE, includes a number of updates on risk assessment, management and treatments. Read more
Las fracturas de cadera son el tipo más severo de fractura en pacientes osteoporóticos y presentan una gran preocupación. En general, conducen a discapacidad física a largo plazo, disminuyen la capacidad para llevar a cabo las actividades diarias y vivir independientemente, reducen la calidad de vida y están asociadas a muerte prematura. En el mundo occidental, el riesgo de fracturas de cadera en... Read more
patient sits with doctor
Worldwide, there is growing concern about declining osteoporosis treatment rates. One reason is that, despite the potentially devastating and life-changing consequences of osteoporotic fractures, an increasing number of patients are reluctant to take osteoporosis therapies. Read more
Approximately 80% of those who have already suffered a broken bone due to osteoporosis remain unprotected against the risk of further disabling fractures, according to a new report issued by the International Osteoporosis Foundation (IOF) in anticipation of World Osteoporosis Day. Read more
Below is a Statement issued by IOF to the BMJ in response to: Clinical assessment and management of multimorbidity: summary of NICE guidance. Farmer et al, BMJ 2016; 354: i4843 Read more
The newly revised consensus statement serves to update and expand the areas of consensus following the publication of the Global Consensus on Menopausal Hormone Therapy (MHT) by leading global menopause societies in 2013. At the time, the Global Consensus succeeded in presenting guidelines that have been helpful to both healthcare providers and potential users of MHT. Read more


Subscribe to Treatment